-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ADdp70/A77r/TNrDCfebsqH+nhvPH5FYvtIBMxxbTlbv8yrYgsaSwbSYD4GcSSQj IDqQoDt8jU8nte4wOA6oUw== 0000950162-02-001334.txt : 20021008 0000950162-02-001334.hdr.sgml : 20021008 20021008153044 ACCESSION NUMBER: 0000950162-02-001334 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020629 FILED AS OF DATE: 20021008 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOGEN INC CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 02784130 BUSINESS ADDRESS: STREET 1: 128 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6179952506 MAIL ADDRESS: STREET 1: 128 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] RELATIONSHIP: OTHER IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 3 1 shirepharmform3100802.txt FORM 3 ------------------------------ OMB APPROVAL ------------------------------ OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response.........0.5 ------------------------------ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 (Print or Type Responses) ________________________________________________________________________________ 1. Name and Address of Reporting Person* Shire BioChem Inc. - -------------------------------------------------------------------------------- (Last) (First) (Middle) 275 Armand-Frapper Blvd. - -------------------------------------------------------------------------------- (Street) Laval (Quebec) Canada H7V 4A7 - -------------------------------------------------------------------------------- (City) (State) (Zip) ________________________________________________________________________________ 2. Date of Event Requiring Statement (Month/Day/Year) June 29, 2002 ________________________________________________________________________________ 3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary) ________________________________________________________________________________ 4. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. (IMGN) ________________________________________________________________________________ 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |_| Director |_| 10% Owner |_| Officer (give title below) |X| Other (specify below) See Explanation of Responses below. ________________________________________________________________________________ 6. If Amendment, Date of Original (Month/Day/Year) ________________________________________________________________________________ 7. Individual or Joint/Group Filing (Check Applicable line) |_| Form filed by One Reporting Person |X| Form filed by More than One Reporting Person ================================================================================ Table I -- Non-Derivative Securities Beneficially Owned ================================================================================
3. Ownership Form: 2. Amount of Securities Direct (D) or 1. Title of Security Beneficially Owned Indirect (I) 4. Nature of Indirect Beneficial Ownership (Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5) - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------------------------------ ====================================================================================================================================
FORM 3 (continued) Table II -- Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================
5. Owner- 3. Title and Amount of Securities ship Underlying Derivative Security Form of 2. Date Exercisable (Instr. 4) Derivative and Expiration Date --------------------------------- 4. Conver- Securities: (Month/Day/Year) Amount sion or Direct 6. Nature of ---------------------- or Exercise (D) or Indirect Date Expira- Number Price of Indirect Beneficial 1. Title of Derivative Exer- tion of Derivative (I) Ownership Security (Instr. 4) cisable Date Title Shares Security (Instr. 5) (Instr. 5) - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D - ------------------------------------------------------------------------------------------------------------------------------------ Warrant (Right to buy)(1) 7/31/2000 7/31/2002 Common Stock 782,755 $2.366 D ====================================================================================================================================
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Explanation of Responses: (1) Prior to July 29, 2002, Shire BioChem, a wholly owned subsidiary of Shire Pharmaceuticals Group Plc, was the owner of the warrants listed above, the terms of exercise of which, as to the number of shares, varied with the market price of the common stock. On June 29, 2002, Shire BioChem Inc. could have exercised the warrants listed above for more than 10% of the Immunogen, Inc. common stock based on the average closing price per share of the common stock for the five consecutive trading days preceding such date, which was $2.366. Upon Shire BioChems' exercise of the warrants on July 29, 2902, and at all times since, Shire BioChem has beneficially owned less than 10% of Immunogen's common stock. /s/ Joseph Rus October 3, 2002 - --------------------------------------------- ----------------------- **Signature of Reporting Person Date Name: Joseph Rus Title: President and Chief Executive Officer * If the form is filed by more than one reporting person, see Instruction 5(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Joint Filer Information Name: Shire Pharmaceuticals Group plc Address: Hampshire International Business Park Chineham, Basingstoke Hampshire, England RG24 8EP Designated Filer: Shire BioChem Inc. Issuer & Ticker Symbol: ImmunoGen, Inc. (IMGN) Date of Event Requiring Statement: June 29, 2002 Signature: /s/ Angus Charles Russell -------------------------------------------- Name: Angus Charles Russell Title: Group Finance Director -----END PRIVACY-ENHANCED MESSAGE-----